Announcements Trials
Browse Landscape

Phase

Phase 1 6Phase 2 3Phase NA 1Phase 3 1Phase 1/2 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 13Thoracic 4Head & Neck 4Genitourinary 4Breast 4Gynecologic 3Sarcoma 2Plasma cell 1NET 1Endocrine 1Dermatologic 1CNS 1

Conditions

Neuroendocrine Tumors 43Carcinoma, Neuroendocrine 22Small Cell Lung Carcinoma 13Carcinoma, Non-Small-Cell Lung 12Neoplasms 11Sarcoma 10Lung Neoplasms 9Thyroid Carcinoma, Anaplastic 7Thyroid Cancer, Papillary 7Stomach Neoplasms 7Pheochromocytoma 7Paraganglioma 7Head and Neck Neoplasms 7Gastro-enteropancreatic neuroendocrine tumor 7Carcinoid Tumor 7Thyroid Neoplasms 6Neoplasm Metastasis 6Colorectal Neoplasms 6Ovarian Neoplasms 5Breast Neoplasms 5Uterine Cervical Neoplasms 4Thyroid Diseases 4Thoracic Neoplasms 4Respiratory Tract Neoplasms 4Respiratory Tract Diseases 4Prostatic Neoplasms 4Neuroblastoma 4Neoplasms by Site 4Multiple Endocrine Neoplasia Type 1 4Lung Diseases 4

Interventions

tivozanib 1atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Gallbladder Neoplasms × Endocrine × Clear all
NCT05000294 2026-02-18

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

University of Florida

Phase 1/2 Suspended
29 enrolled
BreastEndocrineGastrointestinalGenitourinaryGynecologicNETSarcoma

Bile Duct Neoplasms, Breast Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vulvar Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡